Cp07036 - aleida h. konynenbelt vs minister of human resources development
THE PENSION APPEALS BOARD IN RE THE CANADA PENSION PLAN BETWEEN:
ALEIDA H. KONYNENBELT Appellant MINISTER OF HUMAN RESOURCES DEVELOPMENT Respondent
Appeal CP07036
The Honourable Mr. Justice F.H. Poulin, Chairman
The Honourable John J. Urie for the Board:
The Appellant appeals the majority decision of a Review Tribunal
dated April 14, 1997, which confirmed the decision of the Respondent Minister
denying her application dated June 15, 1995, for a disability pension as
provided for by Subsection 44(1)(b) of the Canada Pension Plan.
To be eligible for a disability pension, the Appellant must satisfy
two basic requirements: Firstly, she must have made valid contributions to the
Canada Pension Plan for a minimum qualifying period, and secondly, she
must prove, on a balance of probabilities, that her disability, whether physical
or mental, is one that is both “severe and prolonged” as those terms are
defined in Subsection 42(2)(a) of the Act. To be classified as “severe,” the
disability must be such as renders her incapable regularly of pursuing any
substantially gainful occupation and “prolonged” only if it is determined to be
long continued and of indefinite duration or likely to result in death.
The Appellant last met the minimum qualifying period in
December, 1991. She must, therefore, prove that she was disabled no later
The majority decision of the Review Tribunal is succinct so that it
“Majority Decision By: Dr. Kui Lim Lu and Ms. Diane Houston
She applied for disability pension in July 1995, under Bill C-57. Her Minimum Qualifying Period (MQP) was December 1991.
Most of the medical reports on file, as well as, the evidences presented by Mr. and Mrs. Konynenbelt indicated that her disabilities in 1991 were:
(1) High blood pressure (2) Bladder infection (3) Asthma
(1) High blood pressure - Her Lopresor was
discontinued due to concerns about her asthma, and Capoten disagreed with her. However, Adalat 20mg once a day apparently controlled the hypertension well, even up to the present day.
(2) Bladder infection - She has had two vaginal
repairs for prolapsed bladder. The last surgery caused the bladder neck stricture and required a catheter and urinary bag, a common complication of vaginal repair which was corrected with urinary catheter. She has repeated urinary infection which is controlled well with a single dose of Cipro (antibiotic) every two to three months.
(3) Asthma - This condition was diagnosed in 1989
because of coughing, wheezing, and shortness of breath. She developed reaction to Theo-Dur. In 1991, she was hospitalized twice because of associated bronchitis (asthmatic bronchitis). On her discharge the asthma was controlled with Atrovent, Tilade and Beclovent inhalers. Since then she experienced on and off asthma attacks but controlled with the “Inhalers” without hospitalization.
Three years (3) after her MQP she did develop disabling metastatic carcinoma of the breasts. However, there is no medical evidence in 1991 that her condition was severe as defined under the Canada Pension Plan legislation. The appeal is dismissed.”
In a lengthy dissenting opinion, the Chairman of the Review
Tribunal found that during the period from the year of her last employment in
1986 to 1992, the Appellant’s “periods of wellness” were short-lived, irregular
and unpredictable rendering her “incapable regularly of pursuing any
substantially gainful occupation” so that in his opinion “she was in this
condition by December, 1991, if not before.” He also found that the disability
was “prolonged” since it continued at least through 1993, following which, in
1995, she was diagnosed as having breast cancer and that was the final
Further, in the view of the dissenting member, since her
application for pension benefits was filed only in July, 1995, the earliest date
she could be disabled for the purpose of receiving benefits would be fifteen
months previously, namely, April, 1994, and her benefits thus would have
commenced four months later in August, 1994, if his opinion were to prevail. It
did not, of course, in the view of the majority as shown above, and the appeal
There is no question from my review of the documentary medical
evidence of the Appellant’s physicians as well as the oral testimony given by
Dr. J.M. MacDonald, the Respondent’s medical advisor, that there was ample
evidence that the Appellant’s only disabilities in 1991, were:
The only questions then are, were they so severe that she was incapable
regularly of pursuing any substantially gainful occupation as of December,
1991, and were they likely to be long continued and of indefinite duration?
Dr. D.J. Williams, a specialist in respiratory medicine, first saw
the Appellant on January 15, 1991, when she was admitted to hospital for the
first time for an acute asthma attack associated with exposure to irritants such
as dust and smoke. Admission was in part therapeutic to reduce her exposure
to such irritants. Her blood pressure was elevated at that time so that a new
drug was prescribed to reduce the pressure. She was discharged from
On May 1, 1991, she was readmitted for the same symptoms as
in January. The same treatment was prescribed and, as well, she was given
antibiotics intravenously. Her blood pressure had been reduced to what Dr.
MacDonald described as “acceptably controlled.” Dr. Williams did not attend
admission in January, 1991, to the second admission in May, 1991, she may
have been somewhat disabled by her asthmatic attacks, but it was not a
prolonged disability as the fact that Dr. Williams, the respirologist, was not
again consulted would indicate. The report dated June 13, 1991, of Dr. D.Q.
Chu, an allergist, seems to reinforce this view.
As to the elevated blood pressure, the second problem, all
subsequent medical reports seem to support Dr. MacDonald’s view that it was
well under control enabling her to live a normal life, including pursuing an
occupation, insofar as that condition was concerned.
The third disability alleged to be present in 1991, was a urinary
tract infection in December, 1991, which was treated by her family physician,
Dr. E.J. Pauls, with two drugs, noroxin and pyridium, apparently successfully,
in that month and also in January, 1992. Dr. W. Cyr, an anaesthetist, reported
on a cystoscopic examination on November 25, 1991, which revealed no
In his report dated March 8, 1996, Dr. Pauls outlined his patient’s
medical history from December, 1990, to December, 1993, including that
outlined above, and expressed the following opinion: “It is felt throughout this
time that she was disabled in many of the months through December 1990 -
1992 which interfered with her ability to do any employable work. The above
information will confirm this impression.”
Dr. MacDonald, on the other hand, argued that none of the
disabilities referred to by the Review Tribunal were, in 1991, debilitating to the
extent required for them to be described as severe and prolonged. The
subsequent breast cancer discovery in 1994, might well have fallen within that
category, but it was not present in 1991, the key date for the entitlement to a
Because of these conflicting views, it is clear that the Appellant
has failed, on a balance of probabilities, to discharge the onus upon her of
establishing her entitlement to the receipt of a disability pension under the Act
as at December 31, 1991, when she last met the minimum qualifying period.
DATED this 1st day of March, 2000. (signed)
CAFFEINE FACT SHEET: CAFFEINE AND PERFORMANCE INTERNATIONAL FOOD INFORMATION COUNCIL FOUNDATIONCaffeine is one of the most comprehensively studied ingredients in the food supply and has been safely consumed in foods and beverages for centuries. Evidence of caffeine’s beneficial effects on performance, both mental and athletic, is especially strong. Also linked with athletic performance,
SECURPROST Composizione Serenoa Repens 320 mg, Zinco 10 mg, Licopene 50mg, Coenzima Q10 8 mg, Vitamina E 12mcg, Curcumina 5 mg, Selenio 60 mcg, Camellia Sinensis 50 mg Indicazioni Utile nel favorire le funzionalità prostatiche e nel contribuire alla protezione delle cellule dallo stress ossidativo Forma farmaceutica: compresse film rivestite da 1,3 g Confezione: 20 compresse